Biomimetic universal CAR-mesenchymal stem cell nanohybrids for anti-tumor therapy.

ABSTRACT: Current autologous chimeric antigen receptor (CAR)-T cell therapies are hindered by significant challenges, including the lack of off-the-shelf availability, prolonged manufacturing timelines, and inconsistent product quality, which limit their broader application and clinical efficacy. To address these limitations, we developed an innovative universal CAR nanoplatform by engineering mesenchymal stem cells (MSCs) with CAR and integrating them with multifunctional hybrid nanoparticles. This platform leverages the intrinsic tumor-homing properties of MSCs and the specificity of CAR to achieve precise tumor targeting and eradication. Specifically, we targeted C-type lectin-like molecule-1 (CLL-1), a marker specifically expressed on acute myeloid leukemia (AML) blast cells and leukemia stem ce

SUBMITTER: Yang LY 

PROVIDER: S-EPMC12661994 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature